Regarding &quot;Multiple overlapping uncovered stents as an alternative flow-diverting strategy in the management of peripheral and visceral aneurysms&quot; by C. Mattiuz et al.
LETTERS TO THE EDITORRegarding “Multiple overlapping uncovered
stents as an alternative flow-diverting strategy
in the management of peripheral and visceral
aneurysms”We read with great interest the paper by Zang et al1
recently published in the Journal of Vascular Surgery on the
use of multiple overlapping uncovered stents as an alternative
flow-diverting strategy in the management of peripheral and
visceral aneurysms.
Flow-modulator multilayer stents (FMSs) have attracted great
interest in the recent years, their utility in treating arterial aneurysms
being a highly debated topic.2 FMSs have been successfully used in a
number of different conditions, from visceral and peripheral artery
disease to treatment of thoracoabdominal aortic aneurysms, when
standard endovascular therapy was considered unfeasible.3,4
Zhang et al1 report a new technique that achieves flow mod-
ulation by overlapping multiple uncovered metal stents, which
overcomes the technical problems related to the quite unpredict-
able stent shortening that affects the only commercially available
FMS. Moreover, with their technique, Zhang et al1 are able, by
adding a different number of stents, to tailor the therapy case by
case. According to the study, exceptional results may be achieved
with this new technique: 100% technical success, no complications,
and no deaths at 24 months.
Would this be the situation, this new strategy would represent
the definitive solution for such a complex situation. However, is
flow modulation really so good? At present, there are conflicting
data in literature on the topic. FMSs do not immediately exclude
the aneurysmal sac from blood flow, and internal pressure has
been reported to return to pretreatment level within a short time
after FMS deployment.5 Thus, the patient is not immediately pro-
tected by aneurysmal rupture with this technique, and lethal aneu-
rysm rupture after FMS implantation may occur.6
Zhang et al1 report clinical success, defined as “complete
aneurysm thrombosis, aneurysm shrinkage or stabilization,” in
35 of 37 (94.6%) of their patients. Thus, two of 37 (5.4%) of their
patients are supposed to have a still perfused and enlarging aneu-
rysm at 24 months after treatment. No details about management
of those patients are provided.
Open questions remain about the rupture risk of such patients
who underwent treatment with FMS but have still perfused and
enlarging aneurysms. What is the risk of aneurysm rupture in these
patients? When does the treatment with FMS have to be consid-
ered as failed and further therapeutic strategies have to be taken
into consideration?
Moreover, several factors, such as aneurysm morphology,
number and origin of side branches, and the presence of mural
thrombus, have been reported as potentially influencing the final
aneurysm thrombosis, and factors affecting the patency of collat-
eral vessels have not been fully investigated yet2,4
In conclusion, even if flow diversion with FMSs or multiple
overlapping uncovered stents represent an appealing novel treat-
ment for arterial aneurysms, evidence of efficacy of these strategies
is still limited, and further investigations are needed before their
application in every day clinical practice.
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http://dx.doi.org/10.1016/j.jvs.2015.02.055ReplyAs a new alternative in the endovascular management of
complicated peripheral and visceral artery aneurysms where side
branches need to be maintained, the flow-diverting stent has
attracted great attention since its first clinical application in
2008.1 Despite its increasing clinical application, there remain
several controversies regarding its safety and efficacy in the
literature.2,3
In our study, we reported an alternative flow-diverting
strategy using multiple overlapping uncovered stents
(MOUS) in the treatment of peripheral and visceral artery an-
eurysms, with an overall clinical success rate of 94.6% (35 of
37).4 In the remaining two patients, persistent aneurysm sac
residual perfusion over 2 years was noticed, which was consid-
ered as a clinical failure by definition. However, neither pa-
tient presented with an enlarging aneurysm sac during
follow-up, and significant mural thrombus deposition was
noted in both aneurysms (Fig, A and B). No further treat-
ment, therefore, was performed, except strict blood pressure
control and regular follow-up. Although there is no consensus
about the timing when other treatment options, such as open
repair, need be considered in such a situation, at present, we
believe that further intervention would be necessary if aneu-
rysm expansion was observed during follow-up.
A flow-diverting stent might not be able to decrease
the sac pressure like a stent graft. In another study, we269
